Skip to main content

Table 5 Clinicopathological predictors of SLNB in DCIS patients undergoing BCS

From: Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis

Characteristic

BCS (n = 145) (%)

SLNB (n = 54, 37.2%)

None (n = 91, 62.8%)

p-value

Preoperative tumour size, cm

  

 < 0.001

 ≤ 2

27 (26.7)

74 (73.3)

 

 > 2 and ≤ 5

27 (61.4)

17 (38.6)

 

 > 5 cm

0 (0.0)

0 (0.0)

 

Palpability

  

0.011

 Non-palpable

36 (31.6)

78 (68.4)

 

 Palpable

18 (58.1)

13 (41.9)

 

Mammographic calcification

  

0.608

 Present

30 (39.5)

46 (60.5)

 

 Absent

24 (34.8)

45 (65.2)

 

Ultrasonic mass-forming lesions

  

0.012

 Present

42 (45.2)

51 (54.8)

 

 Absent

12 (23.1)

40 (76.9)

 

Tumour location

  

0.071

 Upper-outer

26 (45.6)

31 (54.3)

 

 Upper-inner

13 (61.9)

8 (38.1)

 

 Lower-outer

8 (30.8)

18 (69.2)

 

 Lower-inner

7 (17.1)

34 (82.9)

 

 Multicentric

0 (0.0)

0 (0.0)

 

Biopsy method

  

 < 0.001

 Core-needle biopsy

47 (69.1)

21 (30.9)

 

 VABB

0 (0.0)

6 (100.0)

 

 Excisional biopsy

7 (9.9)

64 (90.1)

 

Comedo necrosis

  

0.007

 Absent

26 (28.6)

65 (71.4)

 

 Present

28 (51.9)

26 (48.1)

 

Main type of DCIS

  

0.002

 Cribriform

18 (25.0)

54 (75.0)

 

 Comedo

29 (55.8)

23 (44.2)

 

 Solid

7 (33.3)

14 (66.7)

 

Nuclear grade

  

0.001

 Low

7 (14.9)

40 (85.1)

 

 Intermediate

29 (46.8)

33 (53.2)

 

 High

18 (50.0)

18 (50.0)

 
  1. BCS breast-conserving surgery, DCIS ductal carcinoma in situ, SLNB sentinel lymph node biopsy, VABB vacuum-assisted breast biopsy